Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res Rep
Hlavní autoři: Kasi, Pashtoon M., Litzow, Mark R., Patnaik, Mrinal M., Hashmi, Shahrukh K., Gangat, Naseema
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4726703/
https://ncbi.nlm.nih.gov/pubmed/26904404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2016.01.002
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky